Regeneron Pharmaceuticals REGN Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's stock issuance proceeds?
- Regeneron Pharmaceuticals (REGN) reported stock issuance proceeds of $163.1M in Q1 2026.
- How has Regeneron Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Regeneron Pharmaceuticals's stock issuance proceeds increased by 169.1% year-over-year, from $60.6M to $163.1M.
- What is the long-term trend for Regeneron Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's stock issuance proceeds has grown at a -21.5% compound annual growth rate (CAGR), from $1.67B to $635.9M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.